Zenflow Spring Implant and Delivery System
Zenflow, Inc. · Decision date Dec 11, 2025
What did the FDA approve?
FDA records P250007 as an original PMA application. The recorded decision is approval, dated Dec 11, 2025.
FDA approval order statement
The Zenflow Spring Implant and Delivery System is indicated for the treatment of obstructive lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) in men with prostatic urethral lengths between 25 and 45 mm and prostate sizes between 25 and 80 cc.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Dec 11, 2025
Regulatory record facts
- Identifier
- P250007
- Regulatory pathway
- Premarket approval application
- Applicant
- Zenflow, Inc.
- Product code
- MER
- Decision code
- APPR
- Decision date
- Dec 11, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT.
- Applicant
- Zenflow, Inc.
- Product code
- MER
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250007 received
Application receipt date recorded by FDA.
P250007 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P250007. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MER
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProVee System for BPHP250011/S005 | Proverum, Ltd. | PMA supplement | Nov 3, 2026 | FDA |
ProVee System for BPHP250011/S006 | Proverum, Ltd. | PMA supplement | Sep 24, 2026 | FDA |
ProVee System for BPHP250011/S004 | Proverum, Ltd. | PMA supplement | Jul 1, 2026 | FDA |
ProVee System for BPHP250011/S003 | Proverum, Ltd. | PMA supplement | Jun 15, 2026 | FDA |
ProVee System for BPHP250011/S002 | Proverum, Ltd. | PMA supplement | Jun 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Zenflow, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 395 Oyster Pt. Blvd., Suite 501, South San Francisco, CA, 94080
Sources and methodology
- Original FDA record: P250007
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



